Source comparison
Pharmacokinetics: Half-Life vs Biological Activity Window
Half-life and biological activity are not the same thing. CJC-1295 no DAC's plasma half-life of 30 minutes means that every 30 minutes, half of the circulating peptide is metabolised or cleared. After four half-lives (roughly 2 hours), 94% of the peptide is go
This comparison does not assign a generated winner or score.
- Half-life and biological activity are not the same thing. CJC-1295 no DAC's plasma half-life of 30 minutes means that every 30 minutes, half of the circulating peptide is metabolised or cleared. After four half-lives (roughly 2 hours), 94% of the peptide is gone. By hour six, plasma levels are functionally undetectable by standard assays. Ipamorelin follows a similar pattern but clears faster. Its half-life is approximately 25 minutes, with near-complete clearance within 2–3 hours.
- The biological activity window extends slightly beyond plasma clearance. Growth hormone pulses triggered by these peptides peak at 15–30 minutes post-injection and remain elevated for 90–120 minutes. This is the clinically relevant window. Not how long trace amounts remain in circulation, but how long the peptides actively occupy receptors and drive GH secretion. Research published in the Journal of Clinical Endocrinology & Metabolism shows that GHRH analogs like CJC-1295 no DAC produce dose-dependent GH responses, with peak serum GH levels occurring at 30 minutes and returning to baseline by 2 hours.
- The absence of Drug Affinity Complex (DAC) in this formulation is what creates the short clearance profile. DAC is a synthetic molecule that binds to serum albumin, extending the peptide's circulation time from hours to days. CJC-1295 with DAC can remain active for 6–8 days, allowing once-weekly dosing. The no-DAC version sacrifices that convenience for control. You can dose multiple times per day to mimic natural GH pulsatility without the risk of chronically elevated GH levels that suppress your body's own production.
- Clearance pathways involve renal filtration and enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV) in plasma. Peptides like these are broken down into amino acid fragments that are either recycled or excreted. There's no tissue accumulation, no depot effect in fat or muscle. Once enzymatic degradation occurs, the peptide is gone. This is why detection windows in anti-doping assays for peptides are measured in hours, not days. Our experience working with CJC1295 Ipamorelin 5MG 5MG research protocols consistently shows this narrow window.